Freeline Therapeutics Holdings plc
FRLN · NASDAQ
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.01 | 0.14 | -0.03 |
| FCF Yield | -302.54% | -158.19% | -37.72% | -48.44% |
| EV / EBITDA | 0.14 | 0.35 | -0.33 | -0.79 |
| Quality | ||||
| ROIC | -168.75% | -118.21% | -41.01% | -74.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.88 | 0.77 | 0.99 | 0.97 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | 23.78% | -14.72% | -76.13% | -87.47% |
| Safety | ||||
| Net Debt / EBITDA | 0.43 | 0.88 | 2.70 | 1.43 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.10 | 0.37 | 0.63 | 1.84 |
| Cash Conversion Cycle | 1,591.38 | 188.02 | -949.10 | -1,174.28 |